🇺🇸 FDA
Patent

US 10201516

Targeting K-Ras-mediated signaling pathways and malignancy by prostratin

granted A61KA61K31/22A61K31/25

Quick answer

US patent 10201516 (Targeting K-Ras-mediated signaling pathways and malignancy by prostratin) held by The Regents of the University of California expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Feb 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/22, A61K31/25, A61K31/7068, A61K45/06